A clinical phase I/II trial with the monoclonal antibody cG250 (RENCAREX®) and interferon-alpha-2a in metastatic renal cell carcinoma patients

M. Siebels; K. Rohrmann; R. Oberneder; M. Stahler; N. Haseke; J. Beck; R. Hofmann; M. Kindler; P. Kloepfer; C. Stief

首页> 外文期刊>World Journal of Urology >A clinical phase I/II trial with the monoclonal antibody cG250 (RENCAREX®) and interferon-alpha-2a in metastatic renal cell carcinoma patients

【24h】

A clinical phase I/II trial with the monoclonal antibody cG250 (RENCAREX®) and interferon-alpha-2a in metastatic renal cell carcinoma patients

机译：单克隆抗体cG250（RENCAREX ®）和干扰素-α-2a在转移性肾细胞癌患者中进行的I / II期临床试验

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Purpose To evaluate the efficacy and safety of WX-G250, a chimeric monoclonal antibody that binds to carboxy anhydrase IX, combined with low-dose interferon-alpha (LD-IFNα) in patients with progressive metastatic renal cell carcinoma (mRCC).

机译：目的为了评估WX-G250（一种结合羧基酸酐酶IX的嵌合单克隆抗体）与低剂量干扰素-α（LD-IFNα）联合治疗进行性转移性肾细胞癌（mRCC）患者的疗效和安全性。

著录项

来源
《World Journal of Urology》 |2011年第1期|p.121-126|共6页
作者
M. Siebels; K. Rohrmann; R. Oberneder; M. Stahler; N. Haseke; J. Beck; R. Hofmann; M. Kindler; P. Kloepfer; C. Stief;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类
关键词

相似文献

外文文献
中文文献
专利

1. A clinical phase I/II trial with the monoclonal antibody cG250 (RENCAREX(R)) and interferon-alpha-2a in metastatic renal cell carcinoma patients. [J] . Siebels M, Rohrmann K, Oberneder R, World journal of urology . 2011,第1期

机译：在转移性肾细胞癌患者中使用单克隆抗体cG250（RENCAREX（R）和干扰素-α-2a）进行的临床I / II期试验。
2. A phase I clinical trial of low-dose interferon-alpha-2A, thalidomide plus gemcitabine and capecitabine for patients with progressive metastatic renal cell carcinoma. [J] . Amato RJ, Khan M Cancer chemotherapy and pharmacology. . 2008,第6期

机译：低剂量干扰素-α2A，沙利度胺加吉西他滨和卡培他滨用于进展性转移性肾细胞癌患者的I期临床试验。
3. A phase I multiple dose,dose escalation study of cG250 monoclonal antibody in patients with advancedrenal cell carcinoma [J] . Alex A. Adjei, Andrew M. Scott, Anthony T. Papenfuss, Cancer immunity . 2007,第2007期

机译：晚期肾细胞癌患者cG250单克隆抗体的I期多剂量，剂量递增研究
4. Designing Phase III Trials in Metastatic Renal Cell Carcinoma: What Are the New Standards? [C] . Ana M. Molina Genitourinary Cancers Symposium . 2012

机译：在转移性肾细胞癌中设计III期试验：新标准是什么？
5. Methodological Approaches for Conducting Claims-Based Studies in Patients Diagnosed with Metastatic Renal Cell Carcinoma [D] . Chun, Danielle S. 2021

机译：用于诊断转移性肾细胞癌的患者的基于权利要求的基于权利要求的方法论方法
6. A phase I multiple dosedose escalation study of cG250 monoclonal antibody in patients with advancedrenal cell carcinoma [O] . Ian D. Davis, Gregory A. Wiseman, Fook-Thean Lee, 2007

机译：一期多次剂量cG250单克隆抗体在晚期患者中的剂量递增研究肾细胞癌
7. A phase II trial of chimeric monoclonal antibody G250 for advanced renal cell carcinoma patients [O] . Bleumer, I, Knuth, A, Oosterwijk, E, 2004

机译：嵌合单克隆抗体G250在晚期肾细胞癌患者中的II期试验

A clinical phase I/II trial with the monoclonal antibody cG250 (RENCAREX®) and interferon-alpha-2a in metastatic renal cell carcinoma patients

摘要

著录项

相似文献

相关主题

期刊订阅